Matthias Guckenberger, Charlotte Billiet, Daniel Schnell, Ciro Franzese, Mateusz Spałek, Susanne Rogers, Jean-Jacques Stelmes, Daniel M Aebersold, Hossein Hemmatazad, Frank Zimmermann, Jörg Zimmer, Thomas Zilli, Alessio Bruni, Brigitta G Baumert, Franziska Nägler, Philipp Gut, Robert Förster, Indira Madani
BACKGROUND: The purpose of this randomised study was to determine whether dose-intensified stereotactic body radiotherapy (SBRT) for painful vertebral metastases results in increased rates of pain improvement compared with conventional external beam radiotherapy (cEBRT) (control) 6 months after treatment. METHODS: This randomized, controlled phase 3 trial was conducted between November 2016 and January 2023, when it was stopped early. Patients were eligible if they were aged 18 years or older; had one or two painful, stable, or potentially unstable vertebral metastases; and had a life expectancy of 1 year or longer according to the investigator's estimates...
April 6, 2024: Cancer